NCNahum Calvo

Nahum Calvo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nahum Calvo has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Albert Pons-Escoda

    Radiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut de Diagnòstic Per La Imatge (IDI), L'Hospitalet de Llobregat, Centre Bellvige, Barcelona, Spain; NeuroOncology Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

    5 shared publications
  • Carles Majós

    Neuro-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain

    5 shared publications
  • Pablo Naval-Baudin

    Radiology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Carrer de Feixa Llarga SN, Barcelona, Spain

    5 shared publications
  • Mònica Cos

    Radiology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Carrer de Feixa Llarga SN, Barcelona, Spain

    4 shared publications
  • Ignacio Martínez-Zalacaín

    Department of Psychiatry, Bellvitge Biomedical Research Institute, Bellvitge University Hospital, Barcelona, Spain; Department of Radiology, Bellvitge University Hospital, Barcelona, Spain

    3 shared publications
  • Pablo Arroyo-Pereiro

    Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

    3 shared publications

Latest Publications

  • Open Access

    3D T1 turbo spin echo improves detection of gadolinium-enhancing multiple-sclerosis lesions

    by Pablo Naval-Baudin, William F. Bermúdez Bravo, Vanessa I. Pineda-Borja, Pablo Arroyo-Pereiro, Ignacio Martínez-Zalacaín, Lucía Romero-Pinel, Paloma Mora, Nahum Calvo, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos, et al.

    Objectives: To compare the performance of 3D T1 turbo spin echo (3DT1TSE) and 3D T1 turbo field echo (3DT1TFE) MRI in detecting gadolinium-enhancing lesions in multiple sclerosis (MS). Materials and methods: We retrospectively analyzed 255 3-T MRIs from MS patients, each including post-contrast 3DT1TSE and 3DT1TFE sequences. Two blinded readers independently assessed enhancing lesions per sequence. A consensus review, incorporating longitudinal imaging and additional sequences, served as the reference standard. Results: The consensus identified 70 enhancing lesions in 31 patients. All 70 were visible on 3DT1TSE, while 64 (91%) were detectable on 3DT1TFE. Reader sensitivity was higher for 3DT1TSE (84% and 90%) than 3DT1TFE (45% and 40%) (p < 0.01). Inter-reader agreement was excellent for 3DT1TSE (ICC = 0.90) and moderate for 3DT1TFE (intraclass correlation coefficient = 0.69). Although false positives were more common with 3DT1TSE, they were readily excluded during consensus reading. In six patients, enhancing lesions were detected only on 3DT1TSE, with treatment escalation in two. Conclusion: 3DT1TSE outperformed 3DT1TFE in sensitivity and reader agreement for enhancing lesion detection in MS. Incorporating 3DT1TSE into standard MRI protocols may improve disease activity assessment and clinical decision-making. Critical relevance statement: Replacing 3D gradient-echo with post-contrast 3D T1 turbo spin-echo brain MRI greatly improves the detection of gadolinium-enhancing multiple-sclerosis lesions, boosting diagnostic sensitivity and reader agreement and directly influencing treatment-escalation decisions in routine practice. Key Points: Detecting and enhancing MS lesions is limited by standard 3D T1 turbo field echo (3DT1TFE) MRI. 3D T1 turbo spin echo detects significantly more gadolinium-enhancing MS lesions than conventional 3DT1TFE. Greater lesion detection allows more precise activity assessment and optimal treatment management. Graphical


  • Open Access

    Improved detection of multiple sclerosis gadolinium-enhancing lesions: 3D T1 Turbo-Spin-Echo Outperforms 3D T1 Turbo-Field Echo MRI

    by Pablo Naval-Baudin, William F Bermúdez Bravo, Vanessa I Pineda-Borja, Pablo Arroyo-Pereiro, Ignacio Martínez-Zalacaín, Lucía Romero, Paloma Mora, Nahum Calvo, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos, et al.

    Objectives To compare the performance of 3D T1 turbo spin echo (3DT1TSE) and 3D T1 turbo field echo (3DT1TFE) MRI in detecting gadolinium-enhancing lesions in multiple sclerosis (MS). Methods We retrospectively analyzed 255 3T MRIs from MS patients, each including post-contrast 3DT1TSE and 3DT1TFE sequences. Two blinded readers independently assessed enhancing lesions per sequence. A consensus review, incorporating longitudinal imaging and additional sequences, served as the reference standard. Results The consensus identified 70 enhancing lesions in 31 patients. All 70 were visible on 3DT1TSE, while 64 (91%) were detectable on 3DT1TFE. Reader sensitivity was higher for 3DT1TSE (84% and 90%) than 3DT1TFE (45% and 40%) (p < 0.01). Inter-reader agreement was excellent for 3DT1TSE (ICC = 0.90) and moderate for 3DT1TFE (ICC = 0.69). Although false positives were more common with 3DT1TSE, they were readily excluded during consensus reading. In six patients, enhancing lesions were detected only on 3DT1TSE, with treatment escalation in two. Conclusion 3DT1TSE outperformed 3DT1TFE in sensitivity and reader agreement for enhancing lesion detection in MS. Incorporating 3DT1TSE into standard MRI protocols may improve disease activity assessment and clinical decision-making.

  • Open Access

    The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis

    by Pablo Naval-Baudin, Albert Pons-Escoda, Albert Castillo-Pinar, Ignacio Martínez-Zalacaín, Pablo Arroyo-Pereiro, Susanie Flores-Casaperalta, Francis Garay-Buitron, Nahum Calvo, Antonio Martínez-Yélamos, Mònica Cos, et al.

    Objectives: Paramagnetic rim lesions (PRLs), usually identified in susceptibility-weighted imaging (SWI), are a promising prognostic biomarker of disability progression in multiple sclerosis (MS). However, SWI is not always available in clinical practice. The objective of this study is to define a novel imaging sign, the T1-dark rim, identifiable in a standard 3DT1 gradient-echo sequence, such as 3D T1 turbo field echo (3DT1FE) and explore its performance as a SWI surrogate to define PRLs. Materials & Methods: This observational cross-sectional study analyzed MS patients who underwent 3T magnetic resonance imaging (MRI) including 3DT1TFE and SWI. Rim lesions were evaluated in 3DT1TFE, processed SWI, and SWI phase and categorized as true positive, false positive, or false negative based on the value of the T1-dark rim in predicting SWI phase PRLs. Sensitivity and positive predictive values of the T1-dark rim for detecting PRLs were calculated. Results: Overall, 80 rim lesions were identified in 63 patients (60 in the SWI phase and 78 in 3DT1TFE; 58 true positives, 20 false positives, and two false negatives). The T1-dark rim demonstrated 97% sensitivity and 74% PPV for detecting PRLs. More PRLs were detected in the SWI phase than in processed SWI (60 and 57, respectively). Conclusion: The T1-dark rim sign is a promising and accessible novel imaging marker to detect PRLs whose high sensitivity may enable earlier detection of smoldering inflammation to guide MS treatment escalation. The relevance of T1-dark rim lesions that are negative on SWI opens up a new field for analysis.

  • Open Access

    Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol

    by X Solanich, A Antolí, N Padullés, M Fanlo-Maresma, A Iriarte, F Mitjavila, O Capdevila, M Molina, J Sabater, J Bas, et al.

    Introduction Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients. Methods and analysis TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature ≤ 37.5°C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours. Discussion Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries. Trial registration number NCT04341038 / EudraCT: 2020-001445-39

  • COVID‐19 and Ischemic Stroke: Clinical and Neuroimaging Findings

    by Pablo Naval‐Baudin, Isabel Rodriguez Caamaño, Cecilia Rubio‐Maicas, Albert Pons‐Escoda, Maria Montserrat Fernández Viñas, Ana Nuñez, Pere Cardona, Carles Majos, Monica Cos, Nahum Calvo

    BACKGROUND AND PURPOSE: SARS‐CoV‐2 causes multiorgan disease due to altered coagulability and microangiopathy. Patients may have an increased risk of cerebrovascular accidents (CVA). Our objective was to analyze clinical and neuroimaging characteristics of patients with ischemic CVA during the pandemic peak in our region, in order to identify atypical presentations.METHODS: We performed a cross‐sectional analysis of patients admitted under code‐stroke protocol to our center with a final diagnosis of ischemic brain infarction. We analyzed the main imaging and demographic characteristics and reviewed neuroimaging for atypical presentations.RESULTS: One‐hundred patients with confirmed ischemic CVA were included. Nineteen had positive polymerase chain reaction testing for SARS‐CoV‐2 on admission. These patients had a lower prevalence of proximal arterial occlusion on imaging, higher in‐hospital mortality, and worse baseline disability. No differences were identified in affected vascular territory, volume of infarction, initial CT stroke score, prevalence of hemorrhagic transformation, gender, age, cardiovascular risk factors, time to admission, symptom severity on entry, or decision to treat with thrombolysis or mechanical thrombectomy. Prevalence of COVID‐19 in our code‐stroke sample was higher than that for our province during this time period.CONCLUSION: The COVID‐19 group had more in‐hospital mortality, less proximal arterial occlusion on CT or MR angiography, and lower baseline modified Rankin Scale score. We suggest a possibly higher proportion of microangiopathic involvement or undetected distal large‐vessel occlusion in the COVID‐19 stroke group. Excess mortality was explained by severe respiratory failure. Otherwise, stroke patients with COVID‐19 did not differ demographically or clinically from those without the illness.


  • Neurologic Involvement in COVID-19: Cause or Coincidence? A Neuroimaging Perspective

    by A. Pons-Escoda, P. Naval-Baudín, C. Majós, A. Camins, P. Cardona, M. Cos, N. Calvo

    SUMMARY: The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has shaken hospitals worldwide. Some authors suggest that neurologic involvement could further complicate the disease. This descriptive study is a cross-sectional review of 103 patients diagnosed with COVID-19 who underwent neuroimaging (of a total of 2249 patients with COVID-19 in our center). Analyzed variables were neurologic symptoms and acute imaging findings. The most frequent symptoms that motivated neuroimaging examinations were mild nonfocal neurologic symptoms, code stroke (refers to patients presenting with signs and symptoms of stroke whose hyperacute assessment and care is prioritized), focal neurologic symptoms, postsedation encephalopathy, and seizures. No cases of encephalitis or direct central nervous system involvement were detected. Thirteen patients presented with acute ischemic events, and 7, with hemorrhagic events; however, most reported multiple vascular risk factors. Despite the large cohort of patients with COVID-19, we found a large number of symptomatic patients with negative neuroimaging findings, and no conclusions can be drawn concerning concrete associations between neuroimaging and COVID-19.